Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Doctoral: Vanier Canada Graduate Scholarships

Université Laval

$150,000.00

Therapeutic potential of Cystamine for Parkinson's disease

FY 2011-12

Summary
Parkinson's disease is mainly characterized by the loss of cells in specific regions of the brain. It is estimated that at the time where the diagnosis is made, approximately 80 percent of the cells that produce dopamine, have already ceased to operate. This leads mainly to movement disorder, but also cognitive symptoms that characterize the disease. Several treatments are available today to control these symptoms. Unfortunately, no drug can halt nor slow down the progression of the disease. Dr. Cicchetti's group has recently demonstrated that cystamine, a chemical compound, is able to prevent the loss of neurons when administered before the onset of the pathological characteristics of the disease. Using mouse models of parkinsonism, we now propose to test, in addition to its neuroprotective capacity, 1) whether cystamine is able to stop, or even reverse neuronal death in Parkinson's disease and 2) identify and understand some of the mechanisms of action for the beneficial effects of cystamine. The results of these studies will be critical to determine the clinical applicability of cystamine for patients suffering from Parkinson's disease.
Program
Doctoral: Vanier Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
247687
Name
Bahremand Arash
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Vanier Canada Graduate Scholarships CIHR
Projecttitle
Therapeutic potential of Cystamine for Parkinson's disease
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Doctoral: Vanier Canada Graduate Scholarships
Keyworddelim
Animal Models; Behavioral Analyses; Bioluminescence Imaging; Cystamine; Neuroprotection; Neurorestoration; Parkinson'S Disease; Post-Mortem Analyses
Abstract
Parkinson's disease is mainly characterized by the loss of cells in specific regions of the brain. It is estimated that at the time where the diagnosis is made, approximately 80 percent of the cells that produce dopamine, have already ceased to operate. This leads mainly to movement disorder, but also cognitive symptoms that characterize the disease. Several treatments are available today to control these symptoms. Unfortunately, no drug can halt nor slow down the progression of the disease. Dr. Cicchetti's group has recently demonstrated that cystamine, a chemical compound, is able to prevent the loss of neurons when administered before the onset of the pathological characteristics of the disease. Using mouse models of parkinsonism, we now propose to test, in addition to its neuroprotective capacity, 1) whether cystamine is able to stop, or even reverse neuronal death in Parkinson's disease and 2) identify and understand some of the mechanisms of action for the beneficial effects of cystamine. The results of these studies will be critical to determine the clinical applicability of cystamine for patients suffering from Parkinson's disease.
Competitiondate
201111
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Bahremand, Arash
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~
Université Laval - $150,000 Grant (2011-12) | Canada Spends